Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 2032-2037

  He, Shiming ^a   Ding, Lianshu ^b   Cao, Yizhan ^a   Li, Gang ^a   Deng, Jianping ^a   Tu, Yanyang ^a   Wang, Boliang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

A disintegrin and metalloprotease 8; Expression; Glioma; Immunohistochemistry; Prognosis; Western blot

Indexed keywords

A DISINTEGRIN AND METALLOPROTEASE 8; ADAM PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; BRAIN TISSUE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR NECROSIS; WESTERN BLOTTING;

ADAM PROTEINS; ADULT; BLOTTING, WESTERN; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84867886232     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0084-9     Document Type: Article

References (16)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007;114:97-109.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
4. Dijkstra A, Postma DS, Noordhoek JA, et al. Expression of ADAMs ("a disintegrin and metalloprotease") in the human lung. Virchows Arch. 2009;454:441-9.
5. Hernández I, Moreno JL, Zandueta C, et al. Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene. 2010;29: 3758-69.
6. Hall T, Pegg LE, Pauley AM, et al. ADAM8 substrate specificity: influence of pH on pre-processing and proteoglycan degradation. Arch Biochem Biophys. 2009;491:106-11.
7. Valkovskaya N, Kayed H, Felix K, et al. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med. 2007;11:1162-74.
8. Naus S, Richter M, Wildeboer D, et al. Ectodomain shedding of the neural recognition molecule CHL1 by the metalloproteasedisintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem. 2004;279:16083-90.
9. Schlomann U, Rathke-Hartlieb S, Yamamoto S, et al. Tumor necrosis factor alpha induces a metalloprotease-disintegrin, ADAM8 (CD156): implications for neuron-glia interactions during neurodegeneration. J Neurosci. 2000;20:7964-71.
10. Ishikawa N, Daigo Y, Yasui W, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res. 2004;10:8363-70.
11. Fritzsche FR, Jung M, Xu C, et al. ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. Virchows Arch. 2006;449:628-36.
12. Wildeboer D, Naus S, Amy Sang QX, et al. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol. 2006;65:516-27.
13. Amour A, Knight CG, English WR, et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. 2002;524:154-8.
14. Valkovskaya NV. Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines. Exp Oncol. 2008;30:129-32.
15. Pagenstecher A, Wussler EM, Opdenakker G, et al. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol. 2001;60:598-612.
16. Roemer A, Schwettmann L, Jung M, et al. The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? J Urol. 2004; 172:2162-6.